Servicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Similares en
SciELO
Compartir
Permalink
Vive Revista de Salud
versión impresa ISSN 2664-3243
Resumen
YUXI BUSTOS, Jessica Roxana y GALLEGOS VINTIMILLA, Santiago Homero. Prevalence of human papilloma virus serotypes in Ecuador women. Vive Rev. Salud [online]. 2021, vol.4, n.11, pp.150-175. ISSN 2664-3243. https://doi.org/10.33996/revistavive.v4i11.93.
The Human Papilloma Virus constitutes a public health problem by presenting a very high prevalence due to the fact that it is one of the most frequent sexually transmitted infections worldwide, it is associated with different types of cancers especially cervical uterine cancer. This cancer is the second cause of death due to oncological diseases in women in Ecuador.
Objective
. The objective of this research was to characterize the infection of Human Papillomavirus from the prevalence of its serotypes associated with cervical lesions in women in Ecuador during the period January 2010 to December 2020.
Methodology
. A systematic documentary review was carried out according to the PRISMA statement. For this purpose, research articles related to the problem were included. The search was carried out in high impact databases such as PubMed, Scopus, ScieLO, Redalyc, Google Scholar, Web of Science, Springer, Taylor & Francis, Elsevier, MedLine; thirty-eight articles were found of which 10 were valid for the research.
Results
. The most prevalent serotypes of Human Papillomavirus in the high oncologic risk group were 16, 58 and 31; while for the low oncologic risk group they were serotypes 61, 81 and 6.
Conclusions
. Not all regions presented studies of HPV serotype prevalence. However, the regions that did present data showed that the most frequent high oncologic risk serotype is 16, while the low oncologic risk serotype is 61.
Palabras clave : Uterine cervical neoplasms; Polymerase chain reaction; Oncologic risk; Human papillomavirus.
